Search All UT System Experts

DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis

J. Zhou, Z. Ning, B. Wang, E. J. Yun, T. Zhang, R. C. Pong, L. Fazli, M. Gleave, J. Zeng, J. Fan, X. Wang, L. Li, J. T. Hsieh, D. He, K. Wu

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis'. Together they form a unique fingerprint.

Medicine & Life Sciences